Abstract |
In preclinical studies, MF59 adjuvant offered improved protection against influenza virus challenge and significantly reduced the viral load in the lungs of challenged mice. In humans, MF59 is a safe and potent vaccine adjuvant that has been licensed in more than 20 countries (Fluad [Novartis Vaccines and Diagnostics Inc., MA, USA]). The safety profile of an MF59-adjuvanted vaccine is well established through a large safety database. MF59 adjuvant has had a significant impact on the immunogenicity of influenza vaccines in the elderly and in adults who are chronically ill. MF59 has also been shown to have a significant impact on the immunogenicity of pandemic influenza vaccines. MF59 allows for broader cross-reactivity against viral strains not included in the vaccine. MF59 has been shown to be more potent for both antibody and T-cell responses than aluminum-based adjuvants. MF59 has broad potential to be used as a safe and effective vaccine adjuvant for a wide range of vaccine types.
|
Authors | Derek T O'Hagan |
Journal | Expert review of vaccines
(Expert Rev Vaccines)
Vol. 6
Issue 5
Pg. 699-710
(Oct 2007)
ISSN: 1744-8395 [Electronic] England |
PMID | 17931151
(Publication Type: Journal Article, Review)
|
Chemical References |
- Adjuvants, Immunologic
- Influenza Vaccines
- MF59 oil emulsion
- Polysorbates
- Squalene
|
Topics |
- Adjuvants, Immunologic
(adverse effects, therapeutic use)
- Animals
- Humans
- Influenza Vaccines
(adverse effects, therapeutic use)
- Influenza, Human
(immunology, prevention & control)
- Orthomyxoviridae
(immunology)
- Polysorbates
(adverse effects, therapeutic use)
- Squalene
(adverse effects, therapeutic use)
|